Lingjie Meng | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Prof. Lingjie Meng | Cancer Cell Biology | Research Excellence Award

Xi’an Jiaotong University | China

Prof. Lingjie Meng is a leading academic in materials chemistry and instrumental analysis, currently serving as Director of the Analysis and Testing Center and Professor at Xi’an Jiaotong University. His research emphasizes advanced materials and analytical techniques, contributing extensively to high-impact scientific journals. With over 180 publications, significant citation impact, and a strong H-index, his work has influenced multiple areas of materials science. He has also secured numerous national patents, reflecting applied innovation. In addition to research, he holds key leadership roles in professional scientific organizations, supporting the development of electron microscopy and inspection technologies at both provincial and national levels.

Citation Metrics (Scopus)

7000
5000
3000
1000
200
50
0

Citations
6,935

Documents
197

h-index
47

Citations

Documents

h-index

Featured Publications

 

 

 

Prof. JY Guo | Cancer Cell Biology | Women Researcher Award

Published on by Cell Biologist

Prof. JY Guo | Cancer Cell Biology | Women Researcher Award

Youjiang Medical University for Nationalities | China

A cross-disciplinary researcher specializing in pharmaceutical and analytical chemistry, with expertise in integrating traditional herbal medicine and modern nanotechnology. Research focuses on isolating bioactive compounds, developing hydrogel-based medical materials, and designing nanoparticle and vaccine systems for cancer therapy. Has led multiple national and regional research projects, published extensively in peer-reviewed journals, and contributed to advancements in biomaterials and drug development. Work also includes metabolomics and mass spectrometry imaging. Actively involved in academic collaborations, editorial responsibilities, and professional organizations, supporting innovation in pharmaceutical sciences and translational medicine.

 

Citation Metrics (Scopus)

800
600
400
200
100
50
0

Citations
718

Documents
16

h-index
10

Citations

Documents

h-index

Featured Publications

Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Sakarie Mustafe Hidig | Cancer Cell Biology | Research Excellence Award

Zhejiang University School of Medicine | United Kingdom

Dr. Sakarie Mustafe Hidig is a General Surgeon, Clinical Researcher, and Editor-in-Chief affiliated with Zhejiang University School of Medicine and the Research Center at Hargeisa Group Hospital. He serves as the UK Country Coordinator for the International Institute of Knowledge Management (TIIKM) and is an active member of the China Medical Association, Somali Medical Association, and the Scholars Academic and Scientific Society. Dr. Hidig has earned multiple international honors, including the SHEN Best Researcher Awards, GCDMSE-2024, and ISSN Research Awards. With over 70 published papers, 280+ SCI editorial handling experiences, and 14 research projects, his work spans general, gastrointestinal, trauma, emergency, hepatobiliary, and pancreatic surgery. He also contributes as an editor for major journals such as PLOS One Medicine, Annals of Medicine and Surgery, Obesity Surgery, and JMIR Public Health and Surveillance. His research interests include surgical oncology, hepatology, pancreatic cancer, and public health.

Citation Metrics (Scopus)

40

30

20

10

0

Citations
12

Documents
7

h-index
2

Citations
Documents
h-index



View Scopus Profile

Featured Publication

Hongjin Liu | Cancer Cell Biology | Research Excellence Award

Published on by Cell Biologist

Dr. Hongjin Liu | Cancer Cell Biology | Research Excellence Award

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College | China

Hongjin Liu is a medical oncologist whose research centers on cancer biology, therapeutic resistance, and tumorigenesis. His work spans molecular oncology, hepatocellular carcinoma, and mechanisms of somatic mutagenesis across human tissues. He has contributed to high-impact studies published in Nature and Signal Transduction and Targeted Therapy, including investigations uncovering the landscape of somatic mutations in normal tissues and the critical role of VAV2 in DNA repair and radiotherapy resistance. His research also explores noncoding RNA–mediated regulatory networks in liver cancer, notably identifying the oncogenic function of ELF3-AS1 through its modulation of the miR-98-5p/CPSF4 axis. Collectively, his publications provide important insights into genomic instability, tumor microenvironment dynamics, and potential molecular targets for improving therapeutic outcomes. His translational research aims to bridge molecular mechanisms with clinical oncology to support precision cancer treatment and advance strategies for overcoming therapy resistance.

Profile: Orcid

Featured Publications: 

1. Ge, P., Niu, S., Fang, M., Xu, Q., Zhang, W., Xu, J., Yang, F., Wang, Y., Shi, T., & Liu, H. (2025). ELF3-AS1 promotes the carcinogenesis of hepatocellular carcinoma cells by inhibiting miR-98-5p/CPSF4 axis. Nucleosides, Nucleotides & Nucleic Acids.

2. Zhang, W., Liu, Z., Liu, H., Huang, Z., Huang, X., Xu, L., Che, X., & Zhan, Z. (2025). The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: A meta-analysis. Frontiers in Immunology.

3. Liu, W., Miao, C., Zhang, S., Liu, Y., Niu, X., Xi, Y., Guo, W., Chu, J., Lin, A., Liu, H., Yang, X., Chen, X., Zhong, C., Ma, Y., Wang, Y., Zhu, S., Liu, S., Tan, W., Lin, D., & Wu, C. (2021). VAV2 is required for DNA repair and implicated in cancer radiotherapy resistance. Signal Transduction and Targeted Therapy, 6(9), 2906–2919.

4. Li, R., Di, L., Li, J., Fan, W., Liu, Y., Guo, W., Liu, W., Liu, L., Li, Q., Chen, L., Chen, Y., Miao, C., Liu, H., Wang, Y., Ma, Y., Xu, D., Lin, D., Huang, Y., Wang, J., Bai, F., & Wu, C. (2021). A body map of somatic mutagenesis in morphologically normal human tissues. Nature, 597(7876), 398–403.

5. Chen, Y., Zeng, Q., Liu, X., Fu, J., Zeng, Z., Zhao, Z., Liu, Z., Bai, W., Dong, Z., & Liu, H. (2018). LINE-1 ORF-1p enhances the transcription factor activity of pregnenolone X receptor and promotes sorafenib resistance in hepatocellular carcinoma cells. Cancer Management and Research, 10, 6345–6358.

Shaoqing Ai | Cancer | Best Researcher Award

Published on by Cell Biologist

Mr. Shaoqing Ai | Cancer | Best Researcher Award

Xi’an Daxing Hospital | China

Dr. Shaoqing Ai’s research focuses on the clinical application and translational potential of integrated traditional Chinese and Western medicine in oncology, particularly in the management of gastrointestinal tumors, lung cancer, and gynecological malignancies. His work emphasizes optimizing multidisciplinary treatment strategies and improving patient outcomes through precision diagnosis and therapy. As an active contributor to the fields of tumor metastasis and geriatric oncology, he has participated in a research project exploring the molecular mechanisms and clinical management of tumor progression and treatment-related complications. His published studies, including one SCI-indexed paper and two Chinese core journal articles, highlight the therapeutic efficacy of combined treatment approaches in reducing radiotherapy- and chemotherapy-induced hematologic toxicities such as leukopenia and thrombocytopenia. Dr. Ai’s research also aims to refine clinical protocols for mitigating adverse effects while enhancing the overall quality of life for cancer patients. Through his involvement in professional oncology committees and collaborative studies, he continues to advance the integration of evidence-based Chinese medicine with modern oncological practices, contributing to the growing body of knowledge supporting individualized and holistic cancer care.

Profile: Orcid

Featured Publications:

Ai, S., Jun, G., Jia, W., & Jie, L. (2025, October 16). Correlation analysis between frequency of gastrointestinal bleeding episodes and abnormal coagulation indexes in digestive system tumors. Scientific Reports. https://doi.org/10.1038/s41598-025-19012-8

 

 

Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Waldemar Debinski | Cancer Cell Biology | Best Researcher Award

Wake Forest School of Medicine | United States

Dr. Waldemar Debinski, M.D., Ph.D., is a distinguished neuroscientist and cancer researcher recognized for his pioneering work in brain tumor biology and targeted molecular therapies. His research focuses on understanding the molecular mechanisms that drive the development and progression of malignant brain tumors, with a particular emphasis on gliomas. Dr. Debinski has significantly contributed to the development of novel targeted therapeutics, including receptor-directed cytotoxins and biologics designed to selectively eliminate tumor cells while sparing healthy tissues. His investigations bridge molecular oncology, translational science, and clinical application, aiming to improve therapeutic outcomes for patients with brain cancers. Throughout his career, he has integrated insights from physiology, molecular biology, and pharmacology to develop translational approaches that move from laboratory discovery to clinical implementation. His extensive research has advanced the understanding of tumor-specific receptors and intracellular signaling pathways, contributing to innovative strategies in cancer immunotherapy and precision medicine. Dr. Debinski’s work exemplifies the integration of basic and clinical research toward the development of next-generation treatments for central nervous system malignancies, positioning him as a leading figure in neuro-oncology and translational cancer research.

Profile: Scopus

Featured Publications:

Wocial, B., Januszewicz, W., Siedlecki, J., Feltynowski, T., & Debinski, W. (1982). Alterations in plasma dopamine-β-hydroxylase and catecholamine concentrations during surgical removal of pheochromocytoma. Endocrinologie, 79, 131–139.

Debinski, W., & Wocial, B. (1982). Various aspects of sodium metabolism in hypertension [in Polish]. Polski Tygodnik Lekarski, 37, 1339–1342.

Ignatowska-Świtalska, H., Debinski, W., & Chojnowski, K. (1983). The role of certain hormonal factors in arterial hypertension [in Polish]. Materia Medica Polona, 15, 74–86.

Wasawska, T., Feltynowski, T., Majewska, Z., Januszewicz, W., Sobolewska-Karwowska, A., Wocial, B., & Debinski, W. (1984). Pheochromocytoma: Description of two cases with an unusual clinical picture [in Polish]. Polski Tygodnik Lekarski, 39, 261–263.

Czarkowski, M., & Debinski, W. (1984). Sodium and primary arterial hypertension [in Polish] (Review). Kardiologia Polska, 27, 967–976.

Wocial, B., Debinski, W., Jablonska-Skwicinska, E., Feltynowski, T., Chodakowska, J., Kozakowska, E., & Januszewicz, W. (1984). Sodium content of erythrocytes in patients with arterial hypertension [in Polish]. Polski Archiwum Medycyny Wewnetrznej, 72, 167–174.

Garcia, R., Debinski, W., Gutkowska, J., Kuchel, O., Thibault, G., Genest, J., & Cantin, M. (1985). Gluco- and mineralocorticoids may regulate the natriuretic effect and the synthesis and release of atrial natriuretic factor by the rat atria in vivo. Biochemical and Biophysical Research Communications, 131, 806–814.

Debinski, W., Kuchel, O., Garcia, R., Buu, N. T., Racz, K., Cantin, M., & Genest, J. (1986). Atrial natriuretic factor inhibits sympathetic activity in one-kidney, one-clip hypertension in the rat. Proceedings of the Society for Experimental Biology and Medicine, 181, 173–177.

Debinski, W., Kuchel, O., Buu, N. T., Garcia, R., Cantin, M., & Genest, J. (1986). Involvement of the adrenal glands in the action of the atrial natriuretic factor. Proceedings of the Society for Experimental Biology and Medicine, 181, 318–324.

Debinski, W., Gutkowska, J., Kuchel, O., Racz, K., Buu, N. T., Cantin, M., & Genest, J. (1986). ANF-like peptide(s) in the peripheral autonomic nervous system. Biochemical and Biophysical Research Communications, 134, 279–284.

Farhad Ghorbani | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Farhad Ghorbani | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Farhad Ghorbani | Shiraz University of Medical Sciences ,Shiraz,Iran | Iran

Dr. Farhad Ghorbani is an esteemed Assistant Professor of Oral and Maxillofacial Surgery at Shiraz University of Medical Sciences, Iran. With over two decades of clinical and academic experience, he has significantly contributed to the fields of oral pathology, trauma, and surgical interventions. A graduate of Kerman University of Medical Sciences, Dr. Ghorbani later specialized further at Shiraz University. His dedication to advancing clinical knowledge is reflected in over a dozen high-impact peer-reviewed publications, focusing on craniofacial abnormalities, surgical outcomes, and rare oral diseases. He is an active researcher with a Scopus Author ID and ORCID, consistently contributing to scientific journals like BMC Oral Health, Scientific Reports, and Maxillofacial Plastic and Reconstructive Surgery. His multidisciplinary collaborations have led to enhanced diagnostic techniques and patient outcomes. Dr. Ghorbani is recognized for both his innovative research and his commitment to medical education.

Publication Profile: 

Orcid

Google Scholar

Education:

Dr. Ghorbani began his medical journey at Kerman University of Medical Sciences, earning his professional doctorate in dentistry (1992–1998). Following years of clinical practice, he advanced his academic and surgical expertise by joining Shiraz University of Medical Sciences in 2013, where he underwent specialized training in Oral and Maxillofacial Surgery and served as an Assistant Professor during his educational tenure (2013–2018). His academic training focused on maxillofacial pathology, surgical techniques, and interdisciplinary diagnostics. The combination of strong foundational medical education and advanced surgical specialization has equipped him with both the theoretical depth and clinical acumen to lead impactful research. His training underlines a commitment to academic excellence and lifelong learning, which is further reflected in his scholarly contributions. Dr. Ghorbani’s educational background bridges foundational dental sciences with advanced surgical innovation.

Experience:

Since December 2018, Dr. Farhad Ghorbani has held the position of Assistant Professor of Oral and Maxillofacial Surgery at Shiraz University of Medical Sciences, Iran. His career blends clinical practice, research, and teaching. Over the years, he has led numerous studies exploring craniofacial morphology, surgical outcomes, dental trauma, and maxillofacial pathologies. He mentors postgraduate students and collaborates with interdisciplinary teams, enhancing diagnostic accuracy and surgical care. His work in both rural and urban settings has exposed him to a wide spectrum of maxillofacial cases, enriching his clinical insights. He actively contributes to improving surgical protocols and patient care standards. Dr. Ghorbani’s experience also includes academic publishing, peer reviews, and participation in scientific forums. He is recognized for his analytical approach and evidence-based practice. His long-standing affiliation with reputed institutions and research groups underscores his strong leadership in oral surgery and academic scholarship.

Research Focus:

Dr. Ghorbani’s primary research interests lie in oral pathology, craniofacial surgery, dentoalveolar trauma, and radiological diagnostics. His work often combines clinical case reports with retrospective analysis, offering insights into rare presentations such as parathyroid carcinoma-linked jaw tumors, and developmental anomalies like concha bullosa. A hallmark of his research is his ability to identify atypical symptoms and connect them with broader systemic conditions, ensuring early diagnosis and management. He has conducted fractal analysis studies to evaluate bone quality, and he explores patient-centered outcomes, such as satisfaction post-rhinoplasty and the psychological impacts of facial surgery. Additionally, his research evaluates the intersection of dental surgery with systemic health—evident in studies related to auditory changes post-orthognathic surgery or the implications of COVID-19 on dental care. Through evidence-based methods and innovative case analyses, Dr. Ghorbani has positioned himself as a thought leader in interdisciplinary oral and maxillofacial research.

Publications Top Notes:

  1. Brown tumors of both jaws as the initial manifestation of parathyroid carcinoma (BMC Oral Health, 2025)

  2. Distribution and laterality of concha bullosa across cranial skeletal types (Maxillofacial Plastic Surg, 2025)

  3. Calcifying Odontogenic Cyst in Posterior Maxilla: A Case Report (Journal of Dentistry Shiraz, 2025)

  4. Central giant cell granuloma mimicking fibro-osseous lesion and hemangioma (J Med Case Reports, 2024)

  5. Fractal CT analysis of mandibular condyles in class III malocclusion (Scientific Reports, 2023)

  6. Patient dissatisfaction following rhinoplasty: A 10-year Iranian study (Maxillofacial Plastic Surg, 2023)

  7. Correlation between impacted third molar and blood group (Int J of Dentistry, 2021)

  8. Effects of orthognathic surgery on auditory function (Maxillofacial Plastic Surg, 2021)

  9. Evaluation of alveolar fractures in trauma patients in Iran (BMC Oral Health, 2021)

  10. Anxiety in patients undergoing mandibular third molar extraction (J Oral Research & Review, 2020)

Conclusion:

In summary, Dr. Farhad Ghorbani embodies the qualities of a deeply committed, analytically skilled, and academically active oral and maxillofacial surgeon. His research is directly informed by his clinical experience, allowing him to bridge theory and practice effectively. His contributions have enriched the literature on oral pathology, surgical complications, facial aesthetics, and patient psychology following treatment interventions. While there are opportunities to expand the scope and scale of his work through more robust methodologies and international collaboration, his existing portfolio already reflects a high standard of academic and clinical integration. Given his track record, ongoing research productivity, and evident commitment to innovation and education, Dr. Ghorbani is a strong and deserving candidate for the Best Researcher Award. With continued growth in research leadership and expanded global outreach, he is poised to make an even greater impact in the years ahead.

Sukanta Nath | Cancer Research | Distinguished Scientist Award

Published on by Cell Biologist

Dr. Sukanta Nath | Cancer Research | Distinguished Scientist Award

Dr. Sukanta Nath, Atal Bihari Vajpayee Regional Cancer Centre, India

Dr. Sukanta Nath is a dedicated Research Scientist with over 13 years of experience in molecular biology, virology, and cancer research. He currently serves at the Atal Bihari Vajpayee Regional Cancer Centre, Agartala, Tripura, where he has led several impactful studies in oral cancer patient care. Holding a Ph.D. in Biotechnology from Gauhati University, Dr. Nath has consistently demonstrated excellence in scientific inquiry, especially in clinical intervention studies. His collaborative works with clinical and academic experts have produced over 10 peer-reviewed publications in reputed journals. Dr. Nath’s research emphasizes evidence-based nursing practices, molecular diagnostics, and the improvement of post-surgical outcomes in cancer patients. Known for his commitment to translational research, Dr. Nath is playing a pivotal role in bridging molecular science with patient-centered care in North-East India. His multidimensional expertise and scholarly contributions make him a deserving candidate for recognition as a Distinguished Scientist.

Publication Profile: 

Scopus

Strengths for the Award:

  1. Extensive Research Experience:
    With over 13 years of hands-on experience in molecular biology, cancer research, and virology, Dr. Nath has a well-established research career that aligns with the award’s standards.

  2. Focused Contributions to Cancer Research:
    His work at Atal Bihari Vajpayee Regional Cancer Centre has significantly contributed to oral cancer patient management, particularly through randomized intervention studies improving postoperative recovery and mental health.

  3. High Research Output:
    He has authored or co-authored 10+ peer-reviewed publications, many of which focus on novel and under-explored aspects such as nursing intervention in cancer care—a progressive and human-centered approach.

  4. Multidisciplinary Approach:
    Dr. Nath bridges molecular diagnostics, clinical research, and public health, evident in his work on HPV molecular epidemiology and AML treatment reviews.

  5. Collaborative and Institutional Impact:
    His collaborations with clinicians, nurses, and academic institutions highlight his team-oriented and translational research vision, helping integrate academic outputs into real-world healthcare.

Areas for Improvement:

  1. International Exposure:
    Dr. Nath could enhance his academic profile with international fellowships, collaborative projects, or presentations at global conferences, which would add broader recognition and perspective to his impactful regional work.

  2. Grant Acquisition & Leadership Roles:
    Documented principal investigator roles or research funding/grant awards would strengthen his leadership credentials in scientific research.

  3. Recognition & Awards:
    While he has a commendable publication record, more national or state-level recognitions, fellowships, or memberships in professional bodies (like ICMR, DBT, etc.) would boost his candidacy for national-level honors.

Education:

Dr. Sukanta Nath’s academic foundation is rooted in the biological sciences, beginning with a B.Sc. in Botany, Zoology, and Physiology from Calcutta University (2003, First Class). He went on to complete his M.Sc. in Biotechnology from Utkal University in 2006, securing First Class (67%). His research potential culminated in a Ph.D. in Biotechnology from Gauhati University, awarded in 2018, where he specialized in molecular biology and translational biomedical science. His education reflects a progressive mastery of theoretical and applied biotechnology, allowing him to engage in complex interdisciplinary research. Despite modest early academic challenges in higher secondary and matriculation, Dr. Nath’s academic trajectory sharply ascended, reflecting perseverance and intellectual growth. His doctoral training equipped him with specialized skills in molecular diagnostics, research design, and bioanalytical tools, which now form the backbone of his professional research work in cancer and infectious disease.

Professional Experience:

Dr. Nath is presently serving as a Research Scientist at the Atal Bihari Vajpayee Regional Cancer Centre, Tripura, since April 2020, where he conducts pivotal research on postoperative outcomes and interventions in oral cancer patients. Previously, he worked as a Research Associate at the College of Fisheries, Central Agricultural University, Tripura (2018–2019), contributing to institutional-level biotech projects. In 2017–2018, he served as a Molecular Scientist and Quality Manager at Agility Diagnostics Pvt. Ltd., Delhi, a NABL-accredited molecular diagnostics lab, where he gained valuable experience in molecular testing and lab quality control. With over 13 years of interdisciplinary experience, Dr. Nath has successfully combined clinical and molecular biology expertise, making impactful contributions to oncology, diagnostics, and public health. His adaptability across academic, clinical, and industry environments illustrates his wide-ranging capabilities as a biomedical researcher and project leader.

Awards and Honors:

While specific named awards are not listed in the provided resume, Dr. Sukanta Nath’s contributions have earned peer recognition through frequent lead and co-author roles in high-impact publications. His ongoing collaboration with clinicians, epidemiologists, and nursing researchers has positioned him as a sought-after expert in cancer-related intervention studies in North-East India. He has been an instrumental figure in pioneering randomized clinical studies assessing fatigue, anxiety, and quality of life in post-surgical oral cancer patients—work that has been accepted in internationally indexed journals. His contributions to the molecular epidemiology of HPV in Indian women also reflect national relevance. The volume and scope of his work, alongside a sustained publication record, underline a distinguished career in translational cancer research. Nomination for the Distinguished Scientist Award is a well-aligned recognition of his achievements and continued potential to contribute at the national level.

Research Focus:

Dr. Nath’s primary research interest lies in molecular biology, oncology, and virology, with a strong emphasis on translational studies that impact patient care. He has led intervention-based research evaluating the role of nursing and clinical protocols in improving postoperative recovery among oral cancer patients. His work assesses anxiety, fatigue, and quality of life post-surgery using evidence-based methodologies. Dr. Nath has also contributed significantly to molecular epidemiology, particularly studying the distribution of high-risk HPV genotypes among women in North-East India. His experience in diagnostics and biotech allows him to approach clinical problems from both biomedical and molecular perspectives, making his research integrative and impactful. The focus on nursing intervention studies, rarely explored in Indian cancer centers, demonstrates his commitment to holistic cancer care. His future goals involve scaling such studies to wider patient populations and contributing to national cancer care protocols.

Publications Top Notes:

  1. 📘 Effectiveness of a supportive educational intervention on pain and physical function among patients undergone abdominal surgery: A randomized controlled trial

  2. 📗 Effectiveness of comprehensive nursing intervention on alleviating postoperative fatigue and anxiety in patients with oral cancer

  3. 📕 Molecular epidemiology and genotype distribution of genital high-risk human papillomavirus among women in North–East India

  4. 📙 Effectiveness of Nursing Interventions on Anxiety among Postoperative Oral Cancer Patients in Regional Cancer Centre, Tripura

  5. 📒 Importance of Nursing Intervention in Alleviating Post-Surgical Fatigue for Patients with Oral Cancer

  6. 📓 Does comprehensive nursing intervention improve post-surgical anxiety in patients with oral cancer?

  7. 📔 Post-Surgical Evaluation of Quality of Life in Patients with Oral Cancer: An Intervention Study from India

  8. 📚 Assessment of Fatigue and Quality of Life amongst Post-Operative Oral Cancer Patients: A Randomized Case Control Study

  9. 📙 Effect of Comprehensive Nursing Intervention on Anxiety and Quality of Life in Postoperative Patients with Oral Cancer

  10. 📗 Prognosis and Treatment in Acute Myeloid Leukemia: A Comprehensive Review

Conclusion:

Dr. Sukanta Nath has demonstrated dedicated service, innovative research, and strong scientific output in the fields of molecular biology and oncology, particularly with a patient-centric approach to oral cancer care. His work addresses a critical healthcare challenge in North-East India and proposes practical solutions backed by rigorous research methodologies.

 

Mingkun Yu | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Mingkun Yu | Cancer Cell Biology | Best Researcher Award

Dr. Mingkun Yu , Binzhou Medical College Affiliated Traditional Chinese Medicine Hospital(Binzhou Traditional Chinese Medicine Hospital) , China

Dr. Mingkun Yu is an Associate Chief Physician at Binzhou Traditional Chinese Medicine Hospital, affiliated with Binzhou Medical College, China. He is an expert in integrating evidence-based medicine with traditional Chinese and Western medical practices, especially within oncology and ophthalmology. With over five years of clinical experience, Dr. Yu has made significant contributions to the field through impactful clinical research, trial designs, and methodological innovation. He is the recipient of a National Natural Science Foundation of China project and has led the development of national-level guidelines. Dr. Yu’s publications have gained high visibility, with citations and downloads from prestigious journals like BMJ. He collaborates with renowned experts worldwide and actively contributes as a peer reviewer for SCI journals. Known for his meticulous clinical approach and research rigor, Dr. Yu is a rising star in integrative medical science, particularly in addressing patient compliance and advancing myopia-related research strategies.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Academic Excellence
    Dr. Yu has earned advanced degrees from top-tier traditional Chinese medicine institutions in China, culminating in a PhD focused on integrated clinical medicine—a rare and interdisciplinary specialty.

  2. Proven Research Record

    • Published 7 SCI-indexed papers (including in BMJ and Therapeutic Advances in Gastroenterology) and 5 Chinese core journal papers.

    • First/corresponding author impact factor: 18.3; co-author cumulative impact factor: 112.

    • One article with 9248 downloads, another cited 66 times—demonstrating strong academic reach and relevance.

  3. Research Leadership

    • Designed and led multiple RCTs, cohort studies, and cluster RCTs.

    • Principal investigator of a National Natural Science Foundation of China project.

    • Spearheaded the national-level guideline on myopia—a major public health concern in Asia.

  4. Innovative Contributions

    • Introduced target value analysis and conducted extensive patient compliance research in clinical trials.

    • Integrated evidence-based methods with traditional Chinese medicine, a cutting-edge niche in global medical research.

  5. Collaborations & Peer Review

    • Collaborates with global leaders such as Paul Little, Gordon Guyatt, and Lehana Thabane.

    • Reviewer for top SCI journals including European Journal of Integrative Medicine and BMC Geriatrics.

⚙️ Areas for Improvement:

  1. Global Dissemination & Outreach

    • Dr. Yu could further enhance his profile by increasing international speaking engagements, attending more global medical symposia, and joining international research societies.

  2. Books or Monographs

    • No books published yet. Authoring clinical reference books or practitioner guides would boost both practical impact and professional visibility.

  3. Translational Research and Patents

    • With only one published patent, there is scope to convert more research findings into innovative tools, treatments, or technologies for broader clinical application.

  4. Professional Memberships

    • Active memberships in professional research or clinical bodies could enhance his professional network and visibility in award circuits.

📚 Education:

Dr. Yu earned his Master’s degree in Evidence-Based Medicine (Oncology) from Beijing University of Traditional Chinese Medicine in 2021. His academic journey culminated in a PhD in Clinical Medicine (Integrated Traditional Chinese and Western Medicine) from Shandong University of Traditional Chinese Medicine in 2024. Throughout his education, Dr. Yu focused on bridging the gap between traditional Chinese therapeutic principles and contemporary Western medical methodologies. His doctoral research emphasized designing clinical trials, evaluating treatment efficacy using systematic review and meta-analysis, and developing methodologies for improving patient outcomes. His educational background also provided him with comprehensive knowledge in oncology, ophthalmology, acupuncture, and behavioral health, preparing him to implement innovative, integrative solutions in clinical practice. He was mentored by leading figures in evidence-based medicine and engaged in collaborative studies with international researchers, further enriching his global research perspective.

🩺 Experience:

With more than 5 years of experience in clinical medicine, Dr. Mingkun Yu has become a prominent practitioner and researcher in integrated traditional Chinese and Western medical care. As an Associate Chief Physician at Binzhou Traditional Chinese Medicine Hospital, he leads and participates in high-level clinical research projects, including randomized controlled trials and cohort studies. He has contributed to over 7 national-level research projects and served as principal investigator in hospital-based clinical studies. Dr. Yu’s areas of expertise include patient compliance strategies in oncology, evidence synthesis in myopia prevention, and methodological development for clinical trials. He is a frequent presenter at national and international conferences and has served as a reviewer for SCI-indexed journals. Dr. Yu is also involved in writing clinical practice guidelines and has been recognized for his scientific contributions through research awards and publications in high-impact journals.

🔬 Research Focus:

Dr. Mingkun Yu’s research lies at the intersection of evidence-based medicine and integrated Chinese and Western clinical practices. His key focus areas include patient compliance in oncology, risk factor identification and prevention strategies for myopia, and designing robust clinical trials like RCTs, cohort, and cluster studies. He actively develops and applies systematic review methodologies, meta-analyses, and guideline development processes to ensure high-impact clinical outcomes. Dr. Yu has innovated in the area of patient compliance by applying qualitative synthesis and target value analysis, improving retention and adherence in clinical trials. He is particularly invested in the development of guidelines for myopia in children and adolescents and has published widely in SCI journals. His collaboration with global experts such as Paul Little, Gordon Guyatt, and Lehana Thabane strengthens the international relevance of his work. Through this multifaceted research approach, Dr. Yu aims to bridge traditional wisdom with modern scientific rigor.

📝 Publications Top Notes:

📄 Pseudomyopia as an independent risk factor for myopia onset: a prospective cohort study among school-aged children – British Journal of Ophthalmology, 2024
📘 The Process factors and improvement strategies of patient compliance and retention in clinical trials: a synthesis of qualitative research – Inplasy Report, 2021
📚 Berberine for diarrhea in children and adults: a systematic review and meta-analysis – Therapeutic Advances in Gastroenterology, 2020

🧾 Conclusion:

Dr. Mingkun Yu stands out as a highly deserving candidate for the Best Researcher Award due to his cross-disciplinary research integrating traditional Chinese and Western medicine, his leadership in national clinical trials, impactful publications, and commitment to clinical innovation. His scholarly output is not only substantial but also highly cited and widely read, reflecting real-world influence and academic excellence.

With a growing international research presence, a unique focus on culturally integrated methodologies, and an impressive trajectory of innovation and collaboration, Dr. Yu clearly embodies the ideals of a next-generation clinical research leader.

Weifen Zhang | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Weifen Zhang | Cancer Cell Biology | Best Researcher Award

Prof. Weifen Zhang , Shandong Second Medical University , China

Professor Weifen Zhang is a renowned scientist in pharmaceutical sciences, serving as a Professor at the School of Pharmacy, Shandong Second Medical University. She also directs the Shandong Engineering Research Center for Intelligent Materials and Regenerative Medicine and the Pharmaceutical Experimental Teaching Center. With over 50 SCI-indexed publications and 27 national and international patents, her contributions have significantly influenced the development of targeted drug delivery systems and smart biomaterials. A recipient of the State Council Special Allowance and recognized as a Shandong Provincial Outstanding Expert, Professor Zhang combines academic excellence with practical innovation. She has led and collaborated on numerous national-level research projects, focusing on novel therapeutic strategies for cancer, regenerative medicine, and nano-drug technologies. Additionally, she plays a prominent role in scientific publishing as a guest editor and reviewer for leading journals. Her dedication to interdisciplinary research continues to shape the future of pharmaceutical technology.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. 📚 High Research Productivity: Over 50 SCI-indexed publications in high-impact journals such as ACS Applied Materials & Interfaces, Journal of Biomedical Nanotechnology, and Science China Materials.

  2. 💡 Innovation & Intellectual Property: Holds 27 national and international patents, showing a strong translation of academic work into real-world applications.

  3. 🔬 Research Focus & Impact: Cutting-edge work in targeted drug delivery systems, intelligent biomaterials, and regenerative medicine, especially impactful in oncology.

  4. 🎯 Project Leadership: Principal Investigator for multiple nationally funded projects, managing significant funding amounts and driving original discoveries.

  5. 🌐 Academic Influence: Serves as a guest editor and reviewer for leading scientific journals, contributing to quality control and peer knowledge advancement.

  6. 📖 Educational Impact: Contributions to national-level textbooks like Pharmaceutics and Pharmaceutical English highlight her role in shaping future pharmaceutical education.

  7. 🤝 Industry Collaboration: Active collaborations with companies like NOIMAIER (Shandong) Medical Technology Co., Ltd, demonstrating practical application and outreach.

⚠️ Areas for Improvement:

  1. 🌍 Global Outreach: While her influence is strong nationally, increased participation in international conferences, collaborations, and global visibility would further elevate her stature.

  2. 🎙️ Public Engagement: Enhanced involvement in science communication, including talks, public articles, or media, could broaden her societal impact.

  3. 🌐 Online Presence: A more visible online research profile (e.g., Google Scholar, ResearchGate, LinkedIn) could help in networking and research dissemination globally.

🎓 Education:

Professor Weifen Zhang received comprehensive training in pharmaceutical sciences, culminating in a doctorate in pharmacy or a related biomedical field (specific degree and institution not provided in the current profile). Her academic journey has been deeply rooted in advancing applied pharmaceutical research, especially in the field of drug delivery and intelligent materials. Her educational background laid the foundation for her specialization in nanoformulations, regenerative medicine, and drug resistance reversal. Professor Zhang has supplemented her academic credentials with continued professional development through her work with major national science foundations and governmental innovation programs. Her commitment to combining traditional pharmaceutical training with cutting-edge material science has enabled her to become a leader in translational research. Although the detailed degrees and institutions are not specified, her track record in high-impact research, publications, and academic leadership reflects a strong and diverse educational background.

🧪 Experience:

Professor Zhang brings over two decades of experience in pharmaceutical sciences, nanomedicine, and biomaterial engineering. She has served in multiple leadership roles, including Director of both the Shandong Engineering Research Center for Intelligent Materials and Regenerative Medicine and the Pharmaceutical Experimental Teaching Center at Shandong Second Medical University. As Principal Investigator on numerous high-profile projects funded by the National Natural Science Foundation of China and regional innovation programs, she has demonstrated excellence in both basic and translational research. Her industrial collaborations and consultancy projects, such as those with NOIMAIER Medical Technology, reflect her ability to translate scientific innovation into practical solutions. Her experience is also reflected in her active editorial and peer review contributions to top-tier journals, as well as her involvement in educational contributions through national textbook projects. Her academic, industrial, and clinical translational experiences make her a uniquely qualified and impactful researcher.

🔬 Research Focus:

Professor Weifen Zhang’s research is at the forefront of targeted drug delivery, intelligent biomaterials, and regenerative medicine. Her primary scientific focus involves developing novel nanoparticle-based platforms to improve therapeutic outcomes in diseases such as non-small cell lung cancer. She has led pioneering studies in dual-drug synergistic delivery, utilizing agents like quercetin and paclitaxel, aimed at overcoming drug resistance. Her lab also explores smart, biodegradable materials, such as Bletilla striata polysaccharide microneedles, for innovative therapeutic applications including hair regrowth and skin regeneration. In regenerative medicine, she is advancing bionic materials, such as mineralized collagen scaffolds, for orthopedic and dental use. Additionally, she works on plant-derived compounds, contributing to both pharmaceutical and agricultural solutions. Through interdisciplinary approaches, including nanotechnology, immunology, and pharmacokinetics, Professor Zhang’s work is positioned to influence both academic research and clinical practice. Her vision continues to shape the field of personalized and precision medicine.

📚 Publications Top Notes:

  1. 📌 Bletilla striata polysaccharide-based dissolving microneedle patch integrated with nanoparticles for promoting hair regrowth

  2. 🧱 Composite scaffolds based on egg membrane and eggshell-derived inorganic particles promote soft and hard tissue repair

  3. 💉 Efficient chemo-immunotherapy leveraging minimalist electrostatic complex nanoparticle as “in situ” vaccine integrated tumor ICD and immunoagonist

  4. 🌿 A Chinese drug-compatibility-based approach to purslane hydrogels for acute eczema therapy

  5. 🔬 Dynamic Covalent Bond-Based Nanoassembly of Curcumin to Enhance the Selective Photothermal Therapy for Tumor Treatment

  6. 🧵 Multifunctional Nanofiber Membranes Constructed by Microfluidic Blow-Spinning to Inhibit Scar Formation at Early Intervention Stage

  7. 📄 Corrigendum to “Synergistically enhanced cancer immunotherapy by combining protamine-based nanovaccine with PD-L1 gene silence nanoparticle”

  8. 💉 Minimalist “in situ” tumor vaccine leveraging versatile dendrimer nanoplatform coordinated ICD and immunoagonist for boosted chemoimmunotherapy

  9. 🧬 A minimalist cancer cell membrane-shielded biomimetic nanoparticle for nasopharyngeal carcinoma active-targeting therapy

  10. ⚗️ Biodegradable Manganese-Containing Mesoporous Silica Nanoparticles for Precisely Controlled Quercetin Delivery

 

📌 Conclusion:

Professor Weifen Zhang demonstrates exceptional qualifications for the Best Researcher Award. Her deep scientific contributions, robust patent portfolio, influential publications, and national leadership in pharmaceutical innovation mark her as a leader in biomedical research. With a few enhancements in global visibility and science communication, her already impressive profile could reach even greater heights.